Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuropsychiatry Clin Neurosci ; 33(1): 43-48, 2021.
Article in English | MEDLINE | ID: mdl-33086923

ABSTRACT

OBJECTIVE: Despite the high frequency of depression in the first year following stroke, few studies have predicted risk of depression after the acute and subacute stroke periods. The aim of this study was to identify, in the acute and subacute periods, measures that would predict major depression during the first year after stroke. METHODS: Study subjects were inpatients with ischemic stroke aged 20-85 years within 6 weeks of onset. Patients were evaluated at baseline and at 3, 6, 9, and 12 months. Patients were diagnosed with major depression using the Structured Clinical Interview for DSM-IV. The severity of depressive symptoms was measured with the Patient Health Questionnaire-9 (PHQ-9) and the Montgomery-Åsberg Depression Rating Scale (MADRS). RESULTS: Of the 152 potential patients who met inclusion criteria, 49 had follow-up evaluations; one patient with major depression in the acute and subacute periods was excluded from the analysis. Among the remaining 48 patients, the number of those with major depression during the first year of stroke onset was five (10.4%). Patients who developed major depression had significantly more depressive symptoms in the acute and subacute stroke phase as assessed by both the PHQ-9 and MADRS. Patients with PHQ-9 scores ≥9 in the acute and subacute stroke phases were significantly more likely to develop major depression in a chronic phase of stroke. CONCLUSIONS: The self-administered PHQ-9 can identify patients in the acute and subacute stroke periods who are at increased risk for developing major depression during the first year after stroke.


Subject(s)
Depressive Disorder, Major/diagnosis , Predictive Value of Tests , Severity of Illness Index , Stroke/complications , Aged , Female , Humans , Interviews as Topic , Male , Psychiatric Status Rating Scales
2.
Tokai J Exp Clin Med ; 43(2): 64-67, 2018 Jul 20.
Article in English | MEDLINE | ID: mdl-29961934

ABSTRACT

We present a 48-year-old man with a history of hypertension, who suddenly noticed dysarthria and right hemiparesis. Diffusion-weighted MRI at 1 day after the onset showed a small high-intensity region in the left corona radiata, indicating the acute phase of lacunar infarction. Fluid attenuation inversion recovery images showed extensive hyperintense lesions predominantly in the white matter of the fronto-temporoparietal lobes and pons, indicating posterior reversible encephalopathy syndrome (PRES). In addition, T2*-weighted gradient-echo images showed multiple small round hypointense lesions in white matter and basal ganglia, indicating cerebral microbleeds. This is a rare case of symptomatic lacunar infarction accompanied with both PRES and microbleeds, which may suggest that the pathophysiology of PRES is related to hypertension.


Subject(s)
Posterior Leukoencephalopathy Syndrome/etiology , Stroke, Lacunar/etiology , Acute-Phase Reaction , Diffusion Magnetic Resonance Imaging , Humans , Hypertension/complications , Male , Middle Aged , Posterior Leukoencephalopathy Syndrome/diagnostic imaging , Stroke, Lacunar/diagnostic imaging , White Matter/diagnostic imaging
3.
Intern Med ; 56(24): 3357-3359, 2017.
Article in English | MEDLINE | ID: mdl-29249765

ABSTRACT

A 54-year-old woman with adenocarcinoma of the lung and lymph node metastasis experienced nystagmus and cerebellar ataxia 2 weeks after initiating nivolumab therapy. An evaluation for several autoimmune-related antibodies and paraneoplastic syndrome yielded negative results. We eventually diagnosed the patient with nivolumab-induced acute cerebellar ataxia, after excluding other potential conditions. Her ataxic gait and nystagmus resolved shortly after intravenous steroid pulse therapy followed by the administration of decreasing doses of oral steroids. Nivolumab, an immune checkpoint inhibitor, is known to induce various neurological adverse events. However, this is the first report of acute cerebellar ataxia associated with nivolumab treatment.


Subject(s)
Adenocarcinoma/drug therapy , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Cerebellar Ataxia/chemically induced , Cerebellar Ataxia/therapy , Nystagmus, Pathologic/chemically induced , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Female , Humans , Lymph Nodes/physiopathology , Middle Aged , Nivolumab , Treatment Outcome
4.
J Stroke Cerebrovasc Dis ; 26(11): e216-e217, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28843802

ABSTRACT

A 73-year-old man was admitted with sudden right upper-limb weakness. He had a temporal headache on the left side and had a 4-month history of fever. Meandering of the left temporal artery (TA) with induration and high inflammatory responses (white blood cell count 22,500 per microliter, C-reactive protein 35.0 mg/dL, and elevated sedimentation rate [ESR] 80 mm/h) were observed. Glycometabolism and lipid metabolism were normal, and autoimmune antibodies were negative. Cultivation tests revealed no bacteria in either blood culture or cerebrospinal fluid. Brain magnetic resonance imaging (MRI) showed ischemic lesion in the left frontal lobe, while magnetic resonance angiography (MRA) and carotid ultrasonography showed unstable plaque lesions in the left extracranial internal carotid artery (ICA). According to reported criteria (age > 50 years, new onset of headache, abnormality of the TA, and raised ESR), we diagnosed giant cell arteritis (GCA) with acute ischemic stroke (IS) and gave the patient antithrombotic therapy (aspirin 100 mg, cilostazol 200 mg). After admission, hemiparesis progressed but fluctuated. Subsequent MRI showed new lesions in the left watershed area. MRA also showed vasospasm in the middle cerebral artery and C5 portion of the ICA. Considering the correlation with GCA pathophysiology, oral prednisolone therapy was administered. Steroid therapy has prevented stroke recurrence and improved the symptoms and vasospasm. We wish to emphasize that GCA can induce IS via vasospasm, and steroid therapy is recommended.


Subject(s)
Brain Ischemia/complications , Brain Ischemia/etiology , Giant Cell Arteritis/complications , Stroke/etiology , Vasospasm, Intracranial/complications , Vasospasm, Intracranial/etiology , Aged , Brain Ischemia/diagnostic imaging , C-Reactive Protein/metabolism , Humans , Magnetic Resonance Angiography , Magnetic Resonance Imaging , Male , Stroke/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...